BOSTON, Mass. — Almanac Health, a clinical AI and decision support platform founded by physician-researcher Cyril Zakka, M.D., has raised $10 million in a seed funding round led by F-Prime, with participation from General Catalyst and Lightspeed Venture Partners.
The company said General Catalyst previously led its pre-seed round, which also included Soma Capital. With the new financing, Almanac Health’s total funding approaches $12 million. The funds will be used to expand its platform and accelerate efforts to deliver evidence-based AI tools for clinicians and health systems.
Almanac Health is developing a clinical decision support platform designed to integrate into existing electronic health record systems and provide specialist-level insights at the point of care. The company said its system is grounded in peer-reviewed evidence, governed by institutional controls, and is currently undergoing clinical validation in academic medical center settings.
“There is no shortage of technologies promising to transform medicine. But few are grounded in real evidence, built with integrity and deserving of trust from the people and organizations using them. Almanac Health’s goal is to build clinical AI held to that standard. Validated through research, with incentives aligned with clinicians and patients. We’re focused on getting that right,” Zakka said.
Zakka has worked across clinical practice, academic research, and industry, including machine learning research at Stanford, where he developed an early retrieval-augmented generation system for clinical medicine. His work, published in NEJM AI, has been widely cited and helped shape the use of evidence-grounded AI in healthcare. He later led health AI initiatives at Hugging Face before founding Almanac Health.
Carl Byers, partner at F-Prime, said the company reflects a new generation of healthcare AI development.
“Cyril is one of the rare founders who has both the clinical training and the technical depth to build AI that clinicians will actually trust as well as the discipline to validate it before deploying it. Almanac Health represents what we believe the next generation of healthcare AI should look like: grounded in research, governed by institutions, and built with incentives that put clinicians and patients first,” Byers said.
The company plans to use the funding to grow its team across clinical medicine, AI research, and health systems infrastructure, while continuing research and development focused on privacy, reliability, and rigorous evaluation prior to deployment.
Alexandre Momeni, partner at General Catalyst, said the platform aims to bring advanced intelligence directly into clinical workflows.
“We believe the next generation of healthcare infrastructure will be defined by how effectively it translates frontier intelligence into everyday clinical decisions. Almanac is doing exactly that: building a physician-centric platform that brings trusted, evidence-based intelligence into the workflow, with the alignment and accountability required for true health assurance,” Momeni said.
